A detailed history of Wells Fargo & Company transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 17,315 shares of PHAT stock, worth $306,821. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,315
Previous 11,605 49.2%
Holding current value
$306,821
Previous $123,000 44.72%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$8.97 - $12.05 $51,218 - $68,805
5,710 Added 49.2%
17,315 $178,000
Q1 2024

May 10, 2024

BUY
$6.21 - $11.05 $4,440 - $7,900
715 Added 6.57%
11,605 $123,000
Q4 2023

Feb 09, 2024

BUY
$6.99 - $10.71 $25,275 - $38,727
3,616 Added 49.71%
10,890 $99,000
Q3 2023

Nov 13, 2023

SELL
$10.26 - $15.7 $23,844 - $36,486
-2,324 Reduced 24.21%
7,274 $75,000
Q2 2023

Aug 15, 2023

BUY
$7.28 - $14.32 $35,468 - $69,767
4,872 Added 103.09%
9,598 $137,000
Q1 2023

May 12, 2023

BUY
$6.19 - $12.36 $29,253 - $58,413
4,726 New
4,726 $33,000
Q3 2022

Nov 14, 2022

SELL
$6.46 - $12.11 $1,240 - $2,325
-192 Reduced 32.05%
407 $5,000
Q2 2022

Aug 12, 2022

SELL
$6.2 - $15.5 $6,237 - $15,593
-1,006 Reduced 62.68%
599 $5,000
Q1 2022

May 16, 2022

SELL
$11.55 - $20.06 $83,021 - $144,191
-7,188 Reduced 81.75%
1,605 $22,000
Q4 2021

Feb 14, 2022

BUY
$17.83 - $33.15 $156,779 - $291,487
8,793 New
8,793 $173,000
Q2 2021

Aug 16, 2021

SELL
$32.66 - $39.87 $115,191 - $140,621
-3,527 Closed
0 $0
Q1 2021

May 13, 2021

SELL
$33.86 - $48.68 $262,821 - $377,854
-7,762 Reduced 68.76%
3,527 $132,000
Q4 2020

Feb 09, 2021

BUY
$33.22 - $50.26 $88,431 - $133,792
2,662 Added 30.86%
11,289 $375,000
Q3 2020

Nov 05, 2020

SELL
$29.24 - $40.19 $84,211 - $115,747
-2,880 Reduced 25.03%
8,627 $316,000
Q2 2020

Aug 13, 2020

BUY
$25.06 - $54.6 $130,512 - $284,356
5,208 Added 82.68%
11,507 $379,000
Q1 2020

May 14, 2020

BUY
$24.65 - $42.83 $155,270 - $269,786
6,299 New
6,299 $163,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $694M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.